|1.||Yang, Fred: 5 articles (10/2014 - 10/2009)|
|2.||Stewart, Murray: 4 articles (12/2014 - 10/2009)|
|3.||Ye, June: 3 articles (09/2015 - 06/2014)|
|4.||Perry, Caroline: 3 articles (12/2014 - 06/2014)|
|5.||Scott, Rhona: 3 articles (11/2014 - 11/2012)|
|6.||Zhi, Hui: 3 articles (11/2014 - 11/2012)|
|7.||Bush, Mark: 3 articles (06/2014 - 10/2009)|
|8.||Carr, M C: 2 articles (02/2015 - 01/2015)|
|9.||Reinhardt, R R: 2 articles (01/2015 - 12/2014)|
|10.||Carr, Molly C: 2 articles (12/2014 - 10/2014)|
|1.||Type 2 Diabetes Mellitus (MODY)
09/01/2014 - "The recent results from the HARMONY 3 and HARMONY 6 trials suggest that albiglutide is a safe and effective treatment option for patients with type 2 diabetes mellitus."
12/01/2009 - "Weekly and biweekly albiglutide improved glycemic control and were well-tolerated in Japanese subjects with type 2 diabetes mellitus."
06/01/2014 - "Albiglutide exhibited therapeutic hypoglycemic effects with good tolerability among Japanese patients with type 2 diabetes mellitus; the 30 mg weekly dose was the most efficacious in this study. "
06/01/2014 - "A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus."
04/01/2015 - "Albiglutide: a review of its use in patients with type 2 diabetes mellitus."
|2.||Weight Loss (Weight Reduction)
10/01/2009 - "Weekly albiglutide administration significantly improved glycemic control and elicited weight loss in type 2 diabetic patients, with a favorable safety and tolerability profile."
01/01/2015 - "Albiglutide did not cause significant weight loss compared to placebo, but the adverse events profile was favorable with gastrointestinal adverse events occurring only slightly more with albiglutide than placebo. "
10/01/2009 - "Weight loss (-1.1 to -1.7 kg) was observed with these three albiglutide doses with no significant between-group effects. "
12/01/2014 - "Albiglutide was non-inferior to insulin glargine at reducing HbA1c at week 52, with modest weight loss and less hypoglycaemia. "
01/01/2014 - "In the Phase III clinical trials, known as the Harmony series, weekly dosing of albiglutide demonstrated reductions in fasting plasma glucose, postprandial plasma glucose, and glycated hemoglobin, and was associated with weight loss. "
11/01/2014 - "In addition, β-cell secretion is enhanced by albiglutide during hyperglycemia, whereas secretion is suppressed during hypoglycemia; α-cell response to hypoglycemia is not impaired by albiglutide. "
08/01/2014 - "Blinded dose titration for albiglutide (to 50 mg) and glimepiride (to 4 mg) was based on predefined hyperglycemia criteria. "
12/01/2015 - "Shorter-acting GLP-1RAs (exenatide and liraglutide) offer improved coverage of postprandial hyperglycemia, while longer-acting GLP-1RA formulations (exenatide extended-release, dulaglutide, and albiglutide) further improve fasting plasma glucose, which can result in additional A1C lowering. "
07/01/2015 - "The use of albiglutide is contraindicated in patients with a history of pancreatitis and patients with a personal or family history of thyroid cancer. "
05/01/2010 - "There have been no reports to date of development of acute pancreatitis in patients taking albiglutide or taspoglutide. "
05/01/2010 - "Phase 2 and 3 clinical trials evaluating exenatide, liraglutide, albiglutide, and taspoglutide that discussed treatmentrelated adverse effects as well as FDA-reviewed case reports of pancreatitis in patients taking these same therapies were included. "
03/01/2014 - "This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP-1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long-acting exenatide long acting release, albiglutide and dulaglutide."
05/01/2010 - "Key search terms included type 2 diabetes mellitus, pancreatitis, incretins, exenatide, liraglutide, albiglutide, and taspoglutide. "
|4.||Glucagon-Like Peptide 1 (GLP 1)
|10.||glucagon-like peptide receptor (receptor, glucagon-like peptide)